Abstract
In this issue of Cancer Cell, Spitzer and colleagues demonstrate the role of IDH inhibitors on IDHmutant gliomas in reducing proliferation and enhancing cell differentiation toward an astrocytic-like state, thus altering neurodevelopmental pathways. Despite clinical promise, unresolved questions regarding mechanisms of action and resistance underline the need for further research for treatment optimization.
Copyright © 2024 Elsevier Inc. All rights reserved.
MeSH terms
-
Astrocytes / drug effects
-
Astrocytes / metabolism
-
Brain Neoplasms* / drug therapy
-
Brain Neoplasms* / genetics
-
Brain Neoplasms* / pathology
-
Cell Differentiation / drug effects
-
Cell Proliferation / drug effects
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Glioma* / drug therapy
-
Glioma* / genetics
-
Glioma* / pathology
-
Humans
-
Isocitrate Dehydrogenase* / antagonists & inhibitors
-
Isocitrate Dehydrogenase* / genetics
-
Mutation